Cargando…

Therapeutic Effect of Oral Bisphosphonates on Choroidal Neovascularization in the Human Eye

Purpose. Choroidal neovascularization (CNV) is often associated with age-related macular degeneration (AMD) and pathological myopia (PM). Bisphosphonates, the drug of choice to treat osteoporosis, have been recently reported to have anti-angiogenic effects. The purpose of this study is to investigat...

Descripción completa

Detalles Bibliográficos
Autores principales: Honda, Shigeru, Nagai, Takayuki, Kondo, Naoshi, Fukuda, Masahide, Kusuhara, Sentaro, Tsukahara, Yasutomo, Negi, Akira
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2913841/
https://www.ncbi.nlm.nih.gov/pubmed/20706646
http://dx.doi.org/10.1155/2010/206837
_version_ 1782184697605914624
author Honda, Shigeru
Nagai, Takayuki
Kondo, Naoshi
Fukuda, Masahide
Kusuhara, Sentaro
Tsukahara, Yasutomo
Negi, Akira
author_facet Honda, Shigeru
Nagai, Takayuki
Kondo, Naoshi
Fukuda, Masahide
Kusuhara, Sentaro
Tsukahara, Yasutomo
Negi, Akira
author_sort Honda, Shigeru
collection PubMed
description Purpose. Choroidal neovascularization (CNV) is often associated with age-related macular degeneration (AMD) and pathological myopia (PM). Bisphosphonates, the drug of choice to treat osteoporosis, have been recently reported to have anti-angiogenic effects. The purpose of this study is to investigate the therapeutic effects of oral bisphosphonates for CNV in humans. Methods. Thirty-six consecutive cases with CNV due to AMD or PM who declined anti-VEGF therapy were recruited. The patients were prescribed 5 mg of oral alendronates daily for 6 months. The best-corrected visual-acuity (BCVA), the lesion size in fundus photographs and fluorescein angiography, foveal thickness and total macular volume in optical coherence tomography were compared between pre- and post-treatment. Results. The mean BCVA of the patients was significantly improved after a months with the treatment in the AMD group. In the PM group, the mean BCVA was maintained up to 6 months with the treatment. The mean lesion size was significantly decreased by 3 months in both groups. The averages of foveal thickness and total macular volume were significantly reduced after 1 month of treatment in the AMD group.Conclusions. Oral bisphosphonate should be further investigated as a possible therapeutic and preventive drug for CNV due to AMD and PM.
format Text
id pubmed-2913841
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-29138412010-08-12 Therapeutic Effect of Oral Bisphosphonates on Choroidal Neovascularization in the Human Eye Honda, Shigeru Nagai, Takayuki Kondo, Naoshi Fukuda, Masahide Kusuhara, Sentaro Tsukahara, Yasutomo Negi, Akira J Ophthalmol Clinical Study Purpose. Choroidal neovascularization (CNV) is often associated with age-related macular degeneration (AMD) and pathological myopia (PM). Bisphosphonates, the drug of choice to treat osteoporosis, have been recently reported to have anti-angiogenic effects. The purpose of this study is to investigate the therapeutic effects of oral bisphosphonates for CNV in humans. Methods. Thirty-six consecutive cases with CNV due to AMD or PM who declined anti-VEGF therapy were recruited. The patients were prescribed 5 mg of oral alendronates daily for 6 months. The best-corrected visual-acuity (BCVA), the lesion size in fundus photographs and fluorescein angiography, foveal thickness and total macular volume in optical coherence tomography were compared between pre- and post-treatment. Results. The mean BCVA of the patients was significantly improved after a months with the treatment in the AMD group. In the PM group, the mean BCVA was maintained up to 6 months with the treatment. The mean lesion size was significantly decreased by 3 months in both groups. The averages of foveal thickness and total macular volume were significantly reduced after 1 month of treatment in the AMD group.Conclusions. Oral bisphosphonate should be further investigated as a possible therapeutic and preventive drug for CNV due to AMD and PM. Hindawi Publishing Corporation 2010 2010-07-25 /pmc/articles/PMC2913841/ /pubmed/20706646 http://dx.doi.org/10.1155/2010/206837 Text en Copyright © 2010 Shigeru Honda et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Honda, Shigeru
Nagai, Takayuki
Kondo, Naoshi
Fukuda, Masahide
Kusuhara, Sentaro
Tsukahara, Yasutomo
Negi, Akira
Therapeutic Effect of Oral Bisphosphonates on Choroidal Neovascularization in the Human Eye
title Therapeutic Effect of Oral Bisphosphonates on Choroidal Neovascularization in the Human Eye
title_full Therapeutic Effect of Oral Bisphosphonates on Choroidal Neovascularization in the Human Eye
title_fullStr Therapeutic Effect of Oral Bisphosphonates on Choroidal Neovascularization in the Human Eye
title_full_unstemmed Therapeutic Effect of Oral Bisphosphonates on Choroidal Neovascularization in the Human Eye
title_short Therapeutic Effect of Oral Bisphosphonates on Choroidal Neovascularization in the Human Eye
title_sort therapeutic effect of oral bisphosphonates on choroidal neovascularization in the human eye
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2913841/
https://www.ncbi.nlm.nih.gov/pubmed/20706646
http://dx.doi.org/10.1155/2010/206837
work_keys_str_mv AT hondashigeru therapeuticeffectoforalbisphosphonatesonchoroidalneovascularizationinthehumaneye
AT nagaitakayuki therapeuticeffectoforalbisphosphonatesonchoroidalneovascularizationinthehumaneye
AT kondonaoshi therapeuticeffectoforalbisphosphonatesonchoroidalneovascularizationinthehumaneye
AT fukudamasahide therapeuticeffectoforalbisphosphonatesonchoroidalneovascularizationinthehumaneye
AT kusuharasentaro therapeuticeffectoforalbisphosphonatesonchoroidalneovascularizationinthehumaneye
AT tsukaharayasutomo therapeuticeffectoforalbisphosphonatesonchoroidalneovascularizationinthehumaneye
AT negiakira therapeuticeffectoforalbisphosphonatesonchoroidalneovascularizationinthehumaneye